Prolactin and autoimmunity.
The interrelationship between prolactin (PRL) and the immune system have been elucitaded in the last decade, opening new important horizons in the field of the immunoendocrinology. PRL is secreted not only by anterior pituitary gland but also by many extrapituitary sites including the immune cells. The endocrine/paracrine PRL has been shown to stimulate the immune cells by binding to PRL receptors. Increased PRL levels, frequently described in autoimmune diseases, could depend on the enhancement of coordinated bi-directional communications between PRL and the immune system observed in these diseases. Hyperprolactinemia has been described in the active phase of some non organ-specific autoimmune diseases, as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and organ-specific autoimmune diseases, as celiac disease, type 1 diabetes mellitus, Addison's disease, autoimmune thyroid diseases. In these diseases PRL increases the syntesis of IFNgamma and IL-2 by Th1 lymphocytes. Moreover, PRL activates Th2 lymphocytes with autoantibody production. Of particular interest is the association between hyperprolactinemia and levels of anti DNA antibodies, islet cell antibodies (ICA), thyreoglobulin antibodies (TgAb), thyroperoxidase antibodies (TPOAb), adrenocortical antibodies (ACA), transglutaminase antibodies (tTGAb) in SLE, in type 1 diabetes mellitus, in Hashimoto's thyroiditis, in Addison's disease and in celiac disease, respectively. High levels of PRL have been also frequently detected in patients with lymphocytic hypophysitis (LYH). Several mechanisms have been invoked to explain the hyperprolactinemia in LYH. The PRL increase could be secondary to the inflammatory process of the pituitary gland but, on the other hand, this increase could have a role in enhancing the activity of the immune process in LYH. Moreover, the detection of antipituitary antibodies targeting PRL-secreting cells in some patients with idiopathic hyperprolactinemia suggests the occurrence of a possible silent LYH in these patients. Finally, the role of anti-prolactinemic drugs to inactivate the immune process in LYH is still discussed.
De Bellis
Annamaria
A
Department of Clinical and Experimental Medicine and Surgery F. Magrassi, A. Lanzara, Second University of Naples, via Pansini N. 5, 80131, Napoli, Italy. annamaria.debellis@unina2.it
Bizzarro
Antonio
A
Pivonello
Rosario
R
Lombardi
Gaetano
G
Bellastella
Antonio
A
D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000150:complications / Q000503:physiopathology*; D015551:Autoimmunity; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications / Q000276:immunology* / Q000503:physiopathology; D007107:Immune System / Q000378:metabolism / Q000503:physiopathology; D007249:Inflammation; D008214:Lymphocytes; D010900:Pituitary Diseases / Q000150:complications / Q000276:immunology / Q000503:physiopathology; D010902:Pituitary Gland / Q000276:immunology / Q000503:physiopathology; D011388:Prolactin / Q000502:physiology*
D001323:Autoantibodies; D005938:Glucocorticoids; D011388:Prolactin